HALOZYME THERAPEUTICS, INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Halozyme Therapeutics (HALO) won a patent injunction against Merck's Keytruda SC in Europe and expanded its ENHANZE agreement with argenx, adding two more exclusive targets. The company expects US$2.2b revenue and US$1.1b earnings by 2029. Analysts project 9.9% yearly revenue growth, with some predicting significant upside.
A Dutch court ruled Merck's Keytruda Qlex infringes Halozyme's patents, blocking sales in 8 European countries. Halozyme's technology enables rapid delivery of biologics via subcutaneous injections. Enliven Therapeutics aligned with the FDA on a late-stage trial for its leukemia drug relcobatinib, potentially challenging Novartis' and Merck's therapies. Insmed's CFO Sara Bonstein will step down. KymaThera raised $80M for its PI3Kα mutation treatments.
Halozyme Therapeutics (HALO) won a Dutch court case against Merck, halting Merck's Keytruda SC in eight European countries. HALO's stock is trading at $112.16, 10.8% above its GF Value of $101.24, with a GF Score of 89. Insiders sold $41.8M in shares over the past year. The ruling may delay Merck's market entry, preserving HALO's licensing revenue.
Over the past 7 days, AlphAI's AI scored 15 news stories mentioning HALO (HALOZYME THERAPEUTICS, INC.). Coverage has skewed bullish: 13 bullish, 2 neutral, and 0 bearish.
Recent HALO coverage spans regulation, financial news and technology.
In the last 30 days, HALO insiders filed 15 SEC Form 4 transactions — no purchases and 15 sales ($9.1M). The most active reporter was Posard Matthew L. with 8 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Potential boost to Halozyme's royalty revenue from the injunction and expanded partnership.
Positive catalyst for Halozyme's licensing prospects.
Halozyme's patent enforcement strengthens its IP moat and could boost licensing revenue, while Merck faces launch delays.
Court ruling favors Halozyme's technology, potentially boosting its market position.
The injunction may boost Halozyme's stock on the news of a successful IP enforcement while potentially pressuring Merck.
AlphAI scores every news story that mentions HALO with an AI model for sentiment and relevance, and aggregates insider trades from HALOZYME THERAPEUTICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Halozyme Therapeutics (HALO) won a patent injunction against Merck's Keytruda SC in Europe and expanded its ENHANZE agreement with argenx, adding two more exclusive targets. The company expects US$2.2b revenue and US$1.1b earnings by 2029. Analysts project 9.9% yearly revenue growth, with some predicting significant upside.
2 min readA Dutch court ruled Merck's Keytruda Qlex infringes Halozyme's patents, blocking sales in 8 European countries. Halozyme's technology enables rapid delivery of biologics via subcutaneous injections. Enliven Therapeutics aligned with the FDA on a late-stage trial for its leukemia drug relcobatinib, potentially challenging Novartis' and Merck's therapies. Insmed's CFO Sara Bonstein will step down. KymaThera raised $80M for its PI3Kα mutation treatments.
2 min readHalozyme Therapeutics (HALO) won a Dutch court case against Merck, halting Merck's Keytruda SC in eight European countries. HALO's stock is trading at $112.16, 10.8% above its GF Value of $101.24, with a GF Score of 89. Insiders sold $41.8M in shares over the past year. The ruling may delay Merck's market entry, preserving HALO's licensing revenue.
2 min readMerck's shares fell in premarket trading after a Dutch court barred the company from marketing an injectable version of Keytruda in Europe due to a patent dispute with Halozyme. The injunction is part of an ongoing legal battle between the two companies.
1 min readHalozyme secured a court injunction blocking Merck's Keytruda SC in parts of Europe, reinforcing its IP strategy. The impact on Halozyme's finances depends on further legal outcomes.
1 min readHalozyme (HALO) expanded its collaboration with argenx, adding two more exclusive targets for its ENHANZE® technology. The deal strengthens Halozyme's portfolio and reinforces ENHANZE's long-term potential. Halozyme may receive milestone payments and royalties on net sales of products using ENHANZE®.
2 min readHalozyme Therapeutics (HALO) appointed Jim Daly to its Board of Directors. The stock is up 36% over 90 days and 56.25% year-to-date. Analysts debate its valuation, with some calling it 10.4% overvalued at $109.86 versus a fair value estimate of $99.56, while others note its high P/E ratio of 30.1x.
2 min readPosard Matthew L. sold 5,230 shares of HALOZYME THERAPEUTICS, INC. (HALO) at an average of $108.54 ($107.17–$110.04, $0.57M total) across 4 trades on 2026-10-01 under a Rule 10b5-1 trading plan.
1 min readHALOZYME THERAPEUTICS, INC. (HALO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (d) On September 28, 2026, James Daly was elected to the Board of Directors of Halozyme Therapeutics, Inc. (the “Company”)
1 min readHalozyme Therapeutics (HALO) appointed James Daly to its Board of Directors. Daly has over 30 years of biopharmaceutical industry experience, including roles at Incyte, Amgen, and GlaxoSmithKline. He currently serves on the boards of Acadia Pharmaceuticals, Madrigal Pharmaceuticals, and Cytokinetics. Halozyme's stock price was $110.38 on the day of the announcement, slightly below the previous close.
1 min read
